Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
1(7%)
Results Posted
13%(1 trials)

Phase Distribution

Ph phase_3
3
21%
Ph phase_2
2
14%
Ph not_applicable
8
57%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
2(15.4%)
Phase 3Large-scale testing
3(23.1%)
N/ANon-phased studies
8(61.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

1

trials recruiting

Total Trials

14

all time

Status Distribution
Active(1)
Completed(8)
Terminated(1)
Other(4)

Detailed Status

Completed8
unknown4
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (15.4%)
Phase 33 (23.1%)
N/A8 (61.5%)

Trials by Status

recruiting17%
unknown429%
completed857%
withdrawn17%

Recent Activity

1 active trials
Showing 5 of 14
recruitingnot_applicable

Prediction of Blood Pressure Outcomes Following Renal Denervation (PREDICT-RDN)

NCT06845579
withdrawnnot_applicable

Renal Sympathetic Denervation Combined With Aorticorenal Ganglion Ablation for Treatment of Hypertension

NCT06864962
completednot_applicable

Renal Sympathetic Denervation From The Adventitia on Hypertension

NCT02642445
completednot_applicable

REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation

NCT01858194
completed

Systemic Microvascular Function in Patients With Resistant Hypertension After Renal Sympathetic Denervation

NCT03243045
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT06845579Not Applicable

Prediction of Blood Pressure Outcomes Following Renal Denervation (PREDICT-RDN)

Recruiting
NCT06864962Not Applicable

Renal Sympathetic Denervation Combined With Aorticorenal Ganglion Ablation for Treatment of Hypertension

Withdrawn
NCT02642445Not Applicable

Renal Sympathetic Denervation From The Adventitia on Hypertension

Completed
NCT01858194Not Applicable

REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation

Completed
NCT03243045

Systemic Microvascular Function in Patients With Resistant Hypertension After Renal Sympathetic Denervation

Completed
NCT01873352Phase 3

Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation

Completed
NCT02863510Not Applicable

Renal Sympathetic Denervation in Moderate to Severe Chronic Kidney Disease

Completed
NCT01850901Phase 3

Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension

Completed
NCT01630928Not Applicable

Renal Sympathetic Denervation and Potential Effects on Glucose Metabolism and Cardiovascular Risk-Factors

Completed
NCT01840059Phase 2

Renal Denervation in Heart Failure With Preserved Ejection Fraction

Completed
NCT02346045Phase 3

Effect of Renal Denervation in End Staged Renal Disease With Resistant Hypertension

Unknown
NCT01932450Phase 2

Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control

Unknown
NCT01713270Not Applicable

Renal Sympathetic Denervation in Patients With Drug-resistant Hypertension and Symptomatic Atrial Fibrillation

Unknown
NCT01814111Not Applicable

Renal Sympathetic Denervation in Patients With Hypertension and Paroxysmal Atrial Fibrillation

Unknown

All 14 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
14